MASTER COPY

BUREAU OF CUSTOMS

MAKABAGONG ADUANA, MATATAG NA EKONOMIYA

PROFESSIONALISM INTEGRITY ACCOUNTABILITY

AOCG Memo No. 445-2022

MEMORANDUM

TO : **ALL DISTRICT and SUB-PORT COLLECTORS**
ALL CHIEFS, FORMAL ENTRY DIVISION
AND FORMAL ENTRY DIVISION PERSONNEL

FROM : **ATTY. EDWARD JAMES A. DY BUCO**
Deputy Commissioner, AOCG

SUBJECT : **TARIFF COMMISSION CIRCULARS/ADVANCE RULINGS (TCC/AR)**

DATE : 07 December 2022

Pursuant to the provisions of Section 1603 (f) of the Customs Modernization and Tariff Act (Republic Act 10863) and Section 4.9 of Commission Order No. 2017-1 (Procedure on Application for an Advance Ruling on Tariff Classification related to Importation of Goods), the Tariff Commission furnished copies of the Advance Ruling (AR) on Tariff Classification with Tariff Classification Circulars (TCC/AR) issued on 29 November 2022 and the same having been reviewed and summarized as follows:

TCC. NO.	DESCRIPTION OF ARTICLES	2022 AHTN CODE	2022 RATES OF DUTY
22-486	"AMPHOLIP™ (AMPHOTERICIN) 50 mg/10 mL"	3004.20.99	MFN – 5% Ad Valorem AIFTA – Zero*
22-487	"GAMMA.IV™ (NORMAL IMMUNOGLOBULIN (HUMAN))"	3002.12.10	MFN – 1% Ad Valorem AIFTA – Zero*
22-488	"THYMOGAM™ (ANTITHYMOCYTE IMMUNOGLOBULIN (ATG) (EQUINE)"	3002.12.10	MFN – 1% Ad Valorem AIFTA – Zero*
22-489	"AMPHOTRET™ (AMPHOTERICIN B) 50 mg LYOPHILIZED POWDER FOR INJECTION (I.V.)"	3004.20.99	MFN – 5% Ad Valorem AIFTA – Zero*
Subject to submission of their corresponding CERTIFICATES OF ORIGIN (COs).			

AOCG Memo No. 445-2022 p. 2

MASTER COPY

TCC. NO.	DESCRIPTION OF ARTICLES	2022 AHTN CODE	2022 RATES OF DUTY
22-490	"REMIFEMIN®"	3004.90.99	MFN – 5% Ad Valorem
22-491	"POLY-MxB (POLYMYXIN B SULFATE)"	3004.20.99	MFN – 5% Ad Valorem AIFTA – Zero*
22-493	"FOLICULIN™-75 HP (UROFOLLITROPIN FOR INJECTION B.P)"	3004.39.00	MFN – 1% Ad Valorem AIFTA – Zero*
22-494	"ENDOPROST (CARBOPROST TROMETHAMINE)"	3004.39.00	MFN – 1% Ad Valorem AIFTA – Zero*
Subject to submission of their corresponding CERTIFICATES OF ORIGIN (COs).			

For information, guidance and strict compliance.

CC: COMMISSIONER OF CUSTOMS

AOCG Memo No. 445-2022 p 3

MASTER COPY

REPUBLIC OF THE PHILIPPINES
TARIFF COMMISSION

TCOC Ref. No. 22-092

29 November 2022

BUREAU OF CUSTOMS
MESSAGE CENTER
RECEIVED
DEC 01 2022
MERRY ROSE C. MALATE
ADMINISTRATIVE SERVICE OFFICER
TIME: 1035

ACTING COMMISSIONER YOGI FILEMON I. RUIZ
Bureau of Customs
G/F OCOM Building
16th Street, South Harbor
Gate 3 Port Area, Manila

BOC-09-36118

Dear **Acting Commissioner Ruiz**:

Pursuant to the provisions of Section 1603(f) of the Customs Modernization and Tariff Act (Republic Act No. 10863) and Section 4.9 of Commission Order No. 2017-1 (Procedure on Application for an Advance Rulings on Tariff Classification Related to Importation or Exportation of Goods), this Commission is pleased to furnish your good Office with PDF copies of eight Advance Rulings on Tariff Classification, with TCC (AR) Nos. 22-486, 22-487, 22-488, 22-489, 22-490, 22-491, 22-493, and 22-494 issued by this Commission on 29 November 2022. These Advance Rulings have also been posted on the Commission's website *www.tariffcommission.gov.ph*.

Thank you.

Very truly yours,

Digitally signed

MARILOU P. MENDOZA
Chairperson

BUREAU OF CUSTOMS
RECEIVED
BY:
DATE: 1le-6-22
IMPORT ASSESSMENT SERVICE

Encl: *As stated*

cc: *The Secretary*
Department of Finance
Manila

REPUBLIC OF THE PHILIPPINES
BUREAU OF CUSTOMS
OFFICE OF THE DEPUTY COMMISSIONER
ASSESSMENT & OPERATIONS COORDINATING GROUP
RECEIVED
BY:
DATE: 11/29/22
TIME: 3:22

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

01 DEC 2022
10:

AOCG Memo No. 445-2022 p.4

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3004.20.99 **MFN - 5% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-486
3	**DATE ISSUED**
	29 November 2022

4 DESCRIPTION OF GOOD

"AMPHOLIP™ (AMPHOTERICIN B) 50 mg/10 mL"



Based on the product monograph, medical insert, and Certificate of Product Registration from the Food and Drug Administration (FDA) submitted, subject article is a sterile, pyrogen-free suspension of Amphotericin B (a polyene macrolide antifungal antibiotic obtained from a strain of *Streptomyces nodocus*) for intravenous infusion. It is yellow and opaque in appearance containing, per mL of suspension, 5 mg Amphotericin B as the active ingredient. Packed in USP Type 1 borosilicate glass, it is indicated for the treatment of severe systemic fungal infections, including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis, histoplasmosis, mucormycosis, paracoccidioidomycosis, and sporotrichosis, fungal endocarditis, meningitis, peritonitis, and severe respiratory tract infections. Subject article is to be mixed with 5% dextrose injection and administered as a 1 mg/mL infusion mixture.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules, (for example, re-distilled water, in ampoules of 1.25 to 10 cm^3, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use. The heading applies to such single doses whether in bulk, in packings for retail sale, etc.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.99, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) Form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

AOCG Memo No. 445-2022 p 5

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3002.12.10 **MFN - 1% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-487
3	**DATE ISSUED**
	29 November 2022

4 DESCRIPTION OF GOOD

"GAMMA I.V.™ (NORMAL IMMUNOGLOBULIN (HUMAN))"

Based on the product monograph, product insert, Certificate of Product Registration from the Food and Drug Administration (FDA), and photograph of the product submitted, subject article is a human normal immunoglobulin G (IgG) intended for intravenous administration. It is a sterile 4.5 - 5.5% solution of human protein in 9 - 11% maltose with no preservative added. Each mL contains approximately 50 mg protein, not less than 98% of which has electrophoretic mobility of gammaglobulin. Available in 10-mL, 50-mL and 100-mL bottles, it is indicated for the treatment of Primary Immunodeficiency (PID), Kawasaki Syndrome, Idiopathic Thrombocytopenic Purpura (ITP), Guillain-Barre Syndrome (GBS), and bone marrow transplantation.



5 REASONS FOR CLASSIFICATION

Heading 30.02 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers, among others, antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that sera are the fluid fractions separated from blood after clotting. The heading covers, *inter alia*, the following products derived from blood (including vascular endothelial cells): "normal" sera, human normal immunoglobulin, blood fractions and truncated variants (parts) thereof with enzymatic properties/activity, plasma, thrombin, fibrinogen, fibrin and other blood coagulation factors, thrombomodulin, blood globulins, serum globulins, and haemoglobin.

Antisera are obtained from the blood of humans or of animals which are immune or have been immunised against diseases or ailments, whether these are caused by pathogenic bacteria and viruses, toxins or allergic phenomena, etc. Antisera are used against diphtheria, dysentery, gangrene, meningitis, pneumonia, tetanus, staphylococcal or streptococcal infections, snake bite, vegetable poisoning, allergic diseases, etc. Antisera are also used for diagnostic purposes, including in vitro tests. Specific immunoglobulins are purified preparations of antisera.

In view thereof, subject article is classified under AHTN 2022 subheading 3002.12.10, with a Most Favoured Nation (MFN) rate of duty of 1% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) Form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

AOCG Memo No. 445-2022 p.6

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3002.12.10 **MFN - 1% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-488
3	**DATE ISSUED**
	29 November 2022

4 DESCRIPTION OF GOOD

"THYMOGAM™ (ANTITHYMOCYTE IMMUNOGLOBULIN (ATG) (EQUINE))"

Based on the product catalog, medical insert, Certificate of Product Registration from the Food and Drug Administration (FDA) and photograph of the product submitted, subject article is an immunosuppressant drug, *i.e.*, a sterile, antithymocyte globulin in the form of a transparent to slightly opalescent, colourless to pale yellow aqueous solution for intravenous infusion. It is obtained by processing hyper-immune serum of horses immunized with human thymocytes. It is packed in 5-mL vials containing 250 mg antithymocyte globulin (equine), water for injection, glycine (stabilizer), and sodium chloride (excipient). It is used to treat acute rejection episodes in patients who have undergone organ or tissue transplantation. It is also indicated for the treatment of aplastic anemia in patients ineligible for bone marrow transplantation. Subject article is to be diluted before use in sodium chloride injection or in dextrose and sodium chloride.



5 REASONS FOR CLASSIFICATION

Heading 30.02 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers, among others, antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that sera are the fluid fractions separated from blood after clotting. The heading covers, *inter alia*, the following products derived from blood (including vascular endothelial cells): "normal" sera, human normal immunoglobulin, blood fractions and truncated variants (parts) thereof with enzymatic properties/activity, plasma, thrombin, fibrinogen, fibrin and other blood coagulation factors, thrombomodulin, blood globulins, serum globulins, and haemoglobin.

Antisera are obtained from the blood of humans or of animals which are immune or have been immunised against diseases or ailments, whether these are caused by pathogenic bacteria and viruses, toxins or allergic phenomena, etc. Antisera are used against diphtheria, dysentery, gangrene, meningitis, pneumonia, tetanus, staphylococcal or streptococcal infections, snake bite, vegetable poisoning, allergic diseases, etc. Antisera are also used for diagnostic purposes, including in vitro tests. Specific immunoglobulins are purified preparations of antisera.

In view thereof, subject article is classified under AHTN 2022 subheading 3002.12.10, with a Most Favoured Nation (MFN) rate of duty of 1% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) Form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

AOCG Memo No. 445-2022 p-7

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3004.20.99 **MFN - 5% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-489
3	**DATE ISSUED**
	29 November 2022

4 DESCRIPTION OF GOOD

"AMPHOTRET™ (AMPHOTERICIN B) 50 mg LYOPHILIZED POWDER FOR INJECTION (I.V.)"

Based on the product monograph, medical insert, Certificate of Product Registration from the Food and Drug Administration (FDA), and photograph of the product submitted, subject article is a freeze-dried preparation of Amphotericin B (a polyene macrolide antifungal antibiotic obtained from a strain of *Streptomyces nodosus*) for intravenous injection. It is in the form of a yellow cake containing 50 mg Amphotericin B which is required to be reconstituted with sterile water before administration by injection. Available in 10-mL glass vials, subject article is to be administered primarily to patients with progressive, potentially life-threatening fungal infections such as those caused by *Candida spp., Aspergillus spp., Cryptococcus neoformans, Mucor spp., Rhodotorula spp., Absidia spp.,* and *Blastomyces dermatitidis.*



5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules, (for example, re-distilled water, in ampoules of 1.25 to 10 cm^3, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use. The heading applies to such single doses whether in bulk, in packings for retail sale, etc.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.99, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) Form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

AOCG Memo No. 445-2022 p.8

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3004.90.99 **MFN - 5% ad valorem**

2	TCC (AR) NO.
	22-490
3	**DATE ISSUED**
	29 November 2022

4	DESCRIPTION OF GOOD

"REMIFEMIN®"

Based on the product monograph, product insert, Certificate of Product Registration from the Food and Drug Administration (FDA), and photograph of product packaging submitted, subject article is a non-hormonal gynecologic phytomedicine in the form of round, slightly biconvex, whitish-beige 20-mg tablets. It is produced from the medicinal plant *Cimicifuga racemose L.* (black cohosh root and rhizome) via standardized production procedure, with constant monitoring of the contents of active compounds (triterpene glycosides) in combination with other ingredients such as cellulose powder, lactose monohydrate, and magnesium stearate. Packed in boxes containing three blister packs of 20 tablets, subject article is indicated for the symptomatic treatment of menopausal complaints, such as vasomotor symptoms, psychovegetative symptoms, and neurovegetative complaints prior to menstrual bleeding, and in case of painful menstrual bleeding (dysmenorrhea).

5	REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules (for example, re-distilled water, in ampoules of 1.25 to 10 cm^3, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use. The heading applies to such single doses whether in bulk, in packings for retail sale, etc.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.90.99, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem.

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

AOCG Memo No. 445 - 2022 p.9

MASTER COPY

REPUBLIC OF THE PHILIPPINES
TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3004.20.99 **MFN - 5% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-491
3	**DATE ISSUED**
	29 November 2022

4 DESCRIPTION OF GOOD

"POLY-MxB (POLYMYXIN B SULFATE)"



Based on the product monograph, product insert, Certificate of Product Registration from the Food and Drug Administration (FDA), and photographs of the actual product and packaging submitted, subject article is a lyophilized powder of polymyxin (polypeptide antibiotic derived from *Bacillus polymyxa).* It contains 500,000 units of Polymyxin B, as the active ingredient, and is suitable for the preparation of sterile solutions for intramuscular/intravenous drips and for intrathecal or subconjunctival injections. Packed in 5-mL vials, subject article is used for the treatment of intensive care unit (ICU)-acquired infections of various types caused by multidrug-resistant (MDR) gram-negative pathogens, such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Enterobacter* species.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules (for example, re-distilled water, in ampoules of 1.25 to 10 cm^3, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use. The heading applies to such single doses whether in bulk, in packings for retail sale, etc.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.99, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

AOCG Memo No. 445-2022 p.10

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3004.39.00 **MFN - 1% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-493
3	**DATE ISSUED**
	29 November 2022

4 DESCRIPTION OF GOOD

"FOLICULIN™-75 HP (UROFOLLITROPIN FOR INJECTION B.P.)"

Based on the product monograph, product insert, Certificate of Product Registration from the Food and Drug Administration (FDA), and photograph of the product submitted, subject article is urofollitropin (a gonadotropin drug) in the form of a sterile, freeze-dried powder. It is a highly purified urinary follicle stimulating hormone (FSH) derived from human menopausal urine. It has an FSH activity of 75 I.U./150 I.U. and a luteinizing hormone activity of less than 1 I.U./2 I.U. per vial. It is indicated for females with World Health Organization (WHO) Type 2 anovulatory disorders, such as polycystic ovarian syndrome (PCOS). Packed in 1-mL vials, subject article is to be reconstituted with the supplied 1 mL of sodium chloride solution for subcutaneous or intramuscular injection at a dosage depending on the patient's condition.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules (for example, re-distilled water, in ampoules of 1.25 to 10 cm^3, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.39.00, with a Most Favoured Nation (MFN) rate of duty of 1% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) Form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph

AOCG Memo No. 445-2022 p.11

MASTER COPY

REPUBLIC OF THE PHILIPPINES

TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

1	AHTN 2022 CODE AND 2022 RATE/S OF IMPORT DUTY
	AHTN 3004.39.00 **MFN - 1% ad valorem** **AIFTA - Zero**

2	TCC (AR) NO.
	22-494
3	**DATE ISSUED**
	29 November 2022

4	DESCRIPTION OF GOOD

"ENDOPROST (CARBOPROST TROMETHAMINE)"

Based on the product monograph, product insert, Certificate of Product Registration from the Food and Drug Administration (FDA), and photographs of the product submitted, subject article is a clear colorless sterile aqueous solution containing carboprost tromethamine as the active ingredient, and benzyl alcohol, sodium chloride, and small amounts of hydrochloric acid and sodium hydroxide, as excipients. It is a form of prostaglandin that functions as a uterine stimulant, which increases the contractions of the uterus, and consequently stops severe bleeding during childbirth. Available in boxes containing five pieces of 0.5-mL or 1-mL vials, subject article is to be injected intramuscularly for the treatment of postpartum hemorrhage.

5	REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules (for example, re-distilled water, in ampoules of 1.25 to 10 cm^3, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use. The heading applies to such single doses whether in bulk, in packings for retail sale, etc.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.39.00, with a Most Favoured Nation (MFN) rate of duty of 1% ad valorem and ASEAN-India Free Trade Area (AIFTA) rate of duty of zero, subject to submission of Certificate of Origin (CO) Form "AI".

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

MARILOU P. MENDOZA
Chairperson

Note: *In line with the Commission's objective to provide alternative mediums/channels of communication and to further enhance the accessibility of its frontline services to its stakeholders, this Advance Ruling is being issued in digital format, without a dry seal, barcode, and hologram, and is also uploaded in the Tariff Commission website. A hard copy thereof, accompanied by said dry seal, barcode, and hologram, may be issued upon request.*

4th Floor, West Insula Condominium, 135 West Avenue, Quezon City, 1105 Philippines
Tel. Nos.: (632) 8926-8731 / (632) 8928-8419 / (632) 8936-3315 / (632) 8936-3318 • Telefax Number: (632) 8921-7960
Website: tariffcommission.gov.ph • Philippine Tariff Finder: finder.tariffcommission.gov.ph
Email Address: TC.Assist@mail.tariffcommission.gov.ph